// App-Quantinova.ai

275 : NAXIVA: A phase II neoadjuvant study of axitinib for reducing extent of venous tumor thrombus in clear cell renal cell cancer (RCC) with venous invasion.

Researchers

Presenter

  • Grant D. Stewart

Principal Investigators

  • Stephan Ursprung

  • Ferdia Gallagher

  • Iosif Mendichovszky

  • Antony Riddick

  • Tim Eisen

  • Steve Leung

  • Alexander Laird

  • Jahangeer Malik

  • Grenville Oades

  • Balaji Venugopal

  • Faiz Mumtaz

  • Axel Bex

  • Ekaterini Boleti

  • Abdel Hamid

  • Kathleen Riddle

  • Michelle Welsh

  • Lisa Hopcroft

  • Robert J. Jones

Medical Centers

  • University of Cambridge, Cambridge, United Kingdom

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Cambridge University Hospitals, Cambridge, United Kingdom

  • Department of Radiology, Addenbrooke's Hospital, Cambridge, United Kingdom

  • Western General Hospital, Edinburgh, United Kingdom

  • NHS Greater Glasgow & Clyde, Glasgow, United Kingdom

  • University of Glasgow, Glasgow, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Broomfield Hospital, Chelmsford, United Kingdom

  • MRC, Edinburgh, United Kingdom

  • University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

Locations

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Clear cell renal carcinoma

  • Solid malignancies

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Inlyta

Outcome

  • N/A

Study Design

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03494816

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved